A more efficient DNA technology to detect and treat infectious diseases and cancer has been developed by researchers at the Institute of Bioengineering and Nanotechnology (IBN) of A*STAR.
The researchers improved on existing technologies to create a modified single-stranded DNA molecule called aptamer. DNA aptamers are ideal for pharmaceutical applications because they can specifically bind to any molecular target in the body such as proteins, viruses, bacteria and cells.
Once DNA aptamers are artificially generated for each target, they will bind to it and inhibit its activity. This makes DNA aptamers a promising technology for disease detection and drug delivery. But no DNA aptamers have been approved for clinical use yet because current aptamers do not bind well to molecular targets and are easily digested by enzymes.
“To overcome these challenges, we have created a DNA aptamer with strong binding ability and stability with superior efficacy. We hope to use our DNA aptamers as the platform technology for diagnostics and new drug development,” said IBN Executive Director Professor Jackie Y. Ying.
This study, led by IBN Principal Research Scientist and Team Leader Dr Ichiro Hirao, was recently published in the journal, Scientific Reports.
To tackle the weak binding problem, the research team added a new artificial component called unnatural base to a standard DNA aptamer, which typically has four components. The addition of the fifth component greatly enhanced the binding ability to the molecular target by 100 times as compared to conventional DNA aptamers. Furthermore, to prevent the aptamer from being digested easily by enzymes, a unique and small DNA called ‘mini-hairpin DNA’ was added to the DNA aptamer.
Dr Hirao explained, “The mini-hairpin DNAs have an unusually stable and compact stem-loop structure, like a hairpin, of small DNA fragments. Their structure strongly resists the digestive enzymes, so I added them to specific positions on the DNA aptamer to act as a protective shield. Usually DNAs are digested within one hour in blood at body temperature. With the mini-hairpin DNA, our DNA aptamers can survive for days instead of hours. This is important for pharmaceutical applications, which require the therapeutic to remain in the body for a longer period.”
If successfully commercialized, DNA aptamers could replace or complement the existing use of antibodies in drugs for targeted disease treatment. Like aptamers, antibodies bind to targets in the body, but often cause undesirable immune response and are not easy to mass produce with high quality.
“We can now generate very promising DNA aptamers for clinical use. Our aptamers are more efficient, and lower in cost and toxicity compared to conventional methods. The next step of our research is to use the aptamers to detect and deactivate target molecules and cells that cause infectious diseases, such as dengue, malaria and Methicillin-resistant Staphylococcus aureus, as well as cancer,” added Dr Hirao.
Read more: More Efficient DNA Technology for Targeted Disease Detection and Treatment
The Latest on: DNA technology
[google_news title=”” keyword=”DNA technology” num_posts=”10″ blurb_length=”0″ show_thumb=”left”]
via Google News
The Latest on: DNA technology
- Non-Coding DNA Could Explain Childhood Cancer’s Radiotherapy Resistanceon May 2, 2024 at 1:48 am
Scientists at St. Jude Children’s Research Hospital have discovered non-coding genetic variants contributing to chemotherapy resistance in acute lymphoblastic leukemia.
- LPD solves the 1976 murder case of Elizabeth Ann Price with help of new DNA technologyon May 1, 2024 at 10:03 am
In 2002, evidence was submitted to the Lubbock DPS Lab four separate times, hoping that new DNA technology would break the case. However, it did not. The Texas Rangers received the SAKI grant in March ...
- Lubbock Police solves decades old homicide through DNA testingon May 1, 2024 at 8:13 am
The Metropolitan Special Crimes Unit, with the help of multiple law enforcement agencies and DNA testing, has solved the 48-year-old murder of Elizabeth Ann Price.After nearly five decades, it is now ...
- Here’s why Cathie Wood’s Ginkgo Bioworks (DNA) stock has divedon April 30, 2024 at 3:13 am
Cathie Wood, the founder of Ark Invest, is under intense pressure as most of her ETFs implode. The Ark Innovation Fund (ARKK) ETF has crashed by 72% from its highest level in 2021 while the Ark ...
- Man Does DNA Test, Not Prepared For What Comes Back 'Unusually High'on April 30, 2024 at 2:13 am
The designer's genetic profile showed an astonishing amount of Neanderthal DNA, which has captured the attention of millions online—and a scientist.
- At-home DNA test reveals man’s unusual Neanderthal connectionon April 29, 2024 at 8:36 am
Jori Waskahat did an at-home DNA test and found out that he had a Neanderthal DNA. His Instagram post went viral and sparked a much larger discussion.
- Environmental Change, Written in the DNA of Birdson April 29, 2024 at 6:59 am
Two studies of California bird populations show how shifting environments can rewrite animals’ genomes — for better or worse.
- Here is a look at one of the labs that helped uncover new DNA evidence in Lake Oconee murderon April 25, 2024 at 2:07 pm
Police don’t believe the father knew about the pregnancy, but that lead helped them identify Baby India’s biological mother, 40-year-old Karima Juani, who has now been charged with attempted murder, ...
- Vast DNA tree of life for plants revealed by global science team using 1.8 billion letters of genetic codeon April 24, 2024 at 8:00 am
A new paper published today (April 24) in the journal Nature by an international team of 279 scientists led by the Royal Botanic Gardens, Kew presents the most up-to-date understanding of the ...
- DNA Synthesis Approaches: Will New Methods Stand The Test Of Time?on April 24, 2024 at 6:00 am
Both chemical and enzymatic synthesis companies need to continue working to overcome their respective hurdles.
via Bing News